Kite Reports Real-World Analysis Results of Tecartus (brexucabtagene autoleucel) for Relapsed/Refractory Mantle Cell Lymphoma
Shots:
- The real-world analysis of Tecartus showed ORR (90%) which was similar to (ZUMA-2) study results at the median follow-up of 12mos., CR (78%), DoR (64%), PFS (61%) & OS rates (74%) at 12mos., grade ≥3 CRS and ICANS incidence were 10% & 28%, respectively
- In a multivariate analysis, ORR (94%) & CR (88%) who received Tecartus in earlier lines of therapy (1-2 vs ≥3 prior lines of therapy), PFS was improved in patients with prior autoHCT over without prior autoHCT
- In BTKi-naïve patients, effectiveness (ORR 92%, CR 83%) and safety outcomes are consistent over prior BTKi-treated patients. In patients with prior bendamustine use, effectiveness remained consistent, reduction in risk of grade ≥3 ICANS & an increased risk of prolonged thrombocytopenia
Ref: Businesswire | Image: Kite
Related News:- Kite Reports P-I/II Study (ZUMA-3) Results of Tecartus (brexucabtagene autoleucel) for B-Cell Acute Lymphoblastic Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
